Aug 29, 2016
CardioCell offers bright spot in stem cell development
CardioCell reported positive Phase II data for its intravenous stem cell therapy for the treatment of chronic heart failure at the European Society of Cardiology meeting in Rome on Sunday.
The study represented the first positive trial of IV ischemia-tolerant mesenchymal stem cells (itMSCs) in patients with chronic heart failure, after several other companies have failed in the space. READ FULL ARTICLE